Medicenna Therapeutics Corp. (MDNA.TO)
CAD 1.75
(-2.23%)
CAD 1.75
(-2.23%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -16.26 Million | -12.65 Million | -23.58 Million | -15.31 Million | -8.95 Million | -8.03 Million |
| Net Income | -25.46 Million | -10.04 Million | -22.57 Million | -17.28 Million | -8.27 Million | -4.7 Million |
| Depreciation & Amortization | 5000.00 | 4000.00 | 38 Thousand | 40 Thousand | 7892.00 | 6818.00 |
| Deferred income taxes | - | -5.41 Million | 121 Thousand | 267 Thousand | 61.52 Thousand | 628.15 Thousand |
| Stock-based compensation | 1.2 Million | 1.37 Million | 1.41 Million | 1 Million | 1.12 Million | 998.61 Thousand |
| Change in working capital | 741 Thousand | 2.41 Million | -1.84 Million | 680 Thousand | -792.64 Thousand | 683.66 Thousand |
| Other non-cash items | 6.79 Million | -975 Thousand | -737 Thousand | -15 Thousand | -1.07 Million | -5.64 Million |
| Investing Cash Flow | - | -13.04 Million | 10.05 Million | 5.01 Million | -15 Million | -354.45 Thousand |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -10 Million | -10 Million | -15 Million | - |
| Sales/Maturities of investments | - | - | 20.05 Million | 15.01 Million | - | - |
| Other Investing Activities | - | - | 10.05 Thousand | 5013.00 | -15 Thousand | -354.45 Thousand |
| Financing Cash Flow | - | 24.76 Million | 3.87 Million | 18.25 Million | 44.28 Million | 6.82 Million |
| Debt repayment | - | - | -37 Thousand | -39 Thousand | -3393.00 | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 24.76 Million | 3.5 Million | 11.41 Million | 38.37 Million | 3.57 Million |
| Other Financing Activities | - | 24.76 Thousand | 406 Thousand | 6.88 Million | 5.91 Million | 3.24 Million |
| Accounts receivables | 1.67 Million | 1231.00 | -392.00 | -1612.00 | 139.00 | 56.86 |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -937 Thousand | 2.4 Million | -1.84 Million | 681.61 Thousand | -792.78 Thousand | 683.6 Thousand |
| Cash at beginning of period | 33.59 Million | 20.53 Million | 30.37 Million | 22.69 Million | 2.37 Million | 3.93 Million |
| Cash at end of period | 16.98 Million | 33.59 Million | 20.53 Million | 30.37 Million | 22.69 Million | 2.37 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | -354 Thousand | 958 Thousand | -184 Thousand | -281 Thousand | -2857.00 | 31.72 Thousand |
| Net cash flow / Change in cash | -16.61 Million | 13.06 Million | -9.84 Million | 7.67 Million | 20.32 Million | -1.56 Million |
| Free Cash Flow | -16.26 Million | -12.65 Million | -23.58 Million | -15.31 Million | -8.95 Million | -8.03 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -3.63 Million | -13.9 Million | -25.46 Million | -4.97 Million | -3.72 Million | -2.86 Million |
| Depreciation & Amortization | 5000.00 | 1000.00 | 5000.00 | 2000.00 | 1000.00 | 1000.00 |
| Deferred income taxes | - | - | - | 383 Thousand | - | -1.25 Million |
| Stock-based compensation | 433 Thousand | 487 Thousand | 1.2 Million | 159 Thousand | 267 Thousand | 296 Thousand |
| Change in working capital | 943 Thousand | -822 Thousand | 741 Thousand | 718 Thousand | 465 Thousand | 380 Thousand |
| Other non-cash items | 589 Thousand | 9.54 Million | 6.79 Million | -311 Thousand | -931 Thousand | -29 Thousand |
| Investing Cash Flow | -31 Thousand | - | - | - | - | - |
| Investments in PPE | -31 Thousand | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 20.89 Million | - | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 20.89 Million | - | - | - | - | - |
| Other Financing Activities | 20.89 Million | - | - | - | - | - |
| Accounts receivables | -218 Thousand | 340 Thousand | 1.67 Million | 546 Thousand | -155 Thousand | 947.00 |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.16 Million | -1.16 Million | -937 Thousand | 172 Thousand | 620 Thousand | 379.05 Thousand |
| Cash at beginning of period | 16.98 Million | 21.75 Million | 33.59 Million | 25.68 Million | 29.61 Million | 33.59 Million |
| Cash at end of period | 35.62 Million | 16.98 Million | 16.98 Million | 21.75 Million | 25.68 Million | 29.61 Million |
| Capital Expenditure | -31 Thousand | - | - | - | - | - |
| Effect of forex changes on cash | 109 Thousand | 69 Thousand | -354 Thousand | 97 Thousand | -7000.00 | -513 Thousand |
| Net cash flow / Change in cash | 18.64 Million | -4.77 Million | -16.61 Million | -3.92 Million | -3.92 Million | -3.98 Million |
| Free Cash Flow | -2.35 Million | -4.84 Million | -16.26 Million | -4.02 Million | -3.92 Million | -3.46 Million |
300722
AZGFF
002524
SAVA
600368
6093